Correction: Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label randomised controlled ORAL Surveillance trial
Balanescu AR, Citera G, Pascual-Ramos V, et al. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label randomised controlled ORAL Surveillance trial. Ann Rheum Dis 2022;81:1491–503. doi:10.1136/ard-2022-222405.
In Table 3, there was a typographical error in the upper confidence interval of the hazard ratio for ‘history of extra-articular disease: yes versus no’ as a risk factor for serious infection events with tofacitinib 5 mg two times per day. The incorrect value was 1.19, this has now been corrected to 1.91.
The valu...
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Tags: Open access, ARD Correction Source Type: research
Correspondence on 'Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases
We read with great interest the article by Ter Haar et al1 who describe the clinical characteristics, treatment response and genetic findings in a cohort of patients (n=187) with undefined systemic autoinflammatory diseases (sAIDs). The authors observed that patients with pericarditis were older at disease onset and had milder disease whereas patients with intellectual impairment were younger at disease onset and often had affected relatives. Of note, among patients with recurrent disease course, 30% (n=53/180) had aphthous stomatitis. Moreover, after complete gene screening, screening of most relevant exons or screening o...
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Boleto, G., El Chamieh, C., Biard, L., Kone-Paut, I., Hentgen, V., Boursier, G., Sarrabay, G., Cacoub, P., Touitou, I., Saadoun, D. Tags: ARD Correspondence Source Type: research
Methotrexate prolongs TNF inhibitor survival, but only in autoantibody-positive rheumatoid arthritis: a validation study
With great interest, we read the recently published report by Greenwood et al in which the benefits of coprescription of methotrexate (MTX) with tumour necrosis factor (TNF) inhibitors were investigated in autoantibody-positive and autoantibody-negative rheumatoid arthritis (RA) patients. Greenwood et al found a longer TNF inhibitor survival time when the TNF inhibitor was combined with MTX, which only applied for autoantibody-positive RA patients and thus not for autoantibody-negative RA.1 We believe that this finding is of great interest, and relevant, because of its possible implications for treatment with biologics in ...
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: van Mulligen, E., van der Helm-van Mil, A., de Jong, P. H. P. Tags: ARD Correspondence Source Type: research
Correspondence to 'Bacterial citrullinated epitopes generated by Porphyromonas gingivalis infection--a missing link for ACPA production
With great interest, we read the work by Jenning et al, which proposed a mechanism by which Porphyromonas gingivalis (P.g.) is involved in rheumatoid arthritis (RA) progression by citrullinating and producing exogenously citrullinated human and bacterial epitopes.1 This commendable work elucidated the mechanism by which autocitrullinated prokaryotic peptidyl arginine deiminase (PPAD) mediates the inflammatory pathogenesis of RA. In particular, the authors demonstrated a correlation between anti-RA-PPAD and both anticitrullinated peptide/protein antibody (ACPA) levels and interstitial lung disease autoantigen reactivity. Th...
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Ma, K. S.-K., Chiang, C.-H., Chen, Y.-W., Wang, L.-T. Tags: ARD Correspondence Source Type: research
Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine
Mathian et al described the clinical course and heterogeneity of COVID-19 in 17 systemic lupus erythematosus (SLE) patients.1 SLE subjects could be at higher risk of developing COVID-19, with more severe symptomatology and need for hospitalisation due to multiple underlying risk factors.1 2 Type-I interferons (IFN), including IFNα, play fundamental roles in immunity and are crucial in antiviral responses.3 Defects in IFN signalling pathways, secondary to monogenic inborn errors or to blocking autoantibodies, promote immunodeficiency and recurrent infections.4 5 Dysregulation in type-I IFN pathway also plays key patho...
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Gupta, S., Nakabo, S., Chu, J., Hasni, S., Kaplan, M. J. Tags: ARD, COVID-19 Correspondence Source Type: research
Correspondence on 'Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients
The article of interest entitled ‘Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients’, is an important study with the largest cohort of patients with systemic vasculitis (65 patients, 9%).1 Furthermore, 17 patients (26% all vasculitis) had antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.1 The study has many important findings. While risk factors for severe COVID-19 in this large study were similar to those observed in patients with non-rheumatic diseases, vasculitis was found to be an independent risk ...
Source: Annals of the Rheumatic Diseases - September 19, 2023 Category: Rheumatology Authors: Kermani, T. A. Tags: ARD, COVID-19 Correspondence Source Type: research
News from EULAR
EULAR welcomes Daniel Aletaha as new EULAR President EULAR—The European Alliance of Associations for Rheumatology—is pleased to announce a change in its presidency, as Professor Annamaria Iagnocco, Italy, has stepped down as President and handed over the role to Professor Daniel Aletaha, Austria. Professor Aletaha will lead EULAR in its mission to improve the lives of people with rheumatic and musculoskeletal diseases (RMDs), build on EULAR’s successes and drive EULAR forward. He is committed to continuing the work of his predecessor and taking the organisation to even greater heights. The full press rele...
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: EULAR Communications Tags: ARD Eular news Source Type: research
Geyser sign: an indication of chronic shoulder pathology
Presentation An 80-year-old woman presented with pain at rest in the right shoulder. She noted swelling above the acromioclavicular (AC) joint increasing in size over the preceding 6 months. On examination, she was found to have a somewhat firm, non-tender, mobile mass of approximately 4 cm x 5 cm in size above the AC joint. The radiograph showed abnormal soft-tissue density superior to the AC joint. The differential diagnosis included geyser sign, sebaceous cyst, cutaneous neoplasm, subcutaneous lipoma, abscess and Virchow’s node. MRI revealed advanced degenerative change, complete rotator cuff tear and subluxation ...
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Cowley, S., Dempsey, P., McCarthy, G. Tags: ARD, Images in rheumatology Source Type: research
Metabolic rewiring controlled by c-Fos governs cartilage integrity in osteoarthritis
Conclusions
c-Fos modulates cellular bioenergetics in chondrocytes by balancing pyruvate flux between anaerobic glycolysis and the tricarboxylic acid cycle in response to OA signals. We identify a novel metabolic adaptation of chondrocytes controlled by c-Fos-containing AP-1 dimers that could be therapeutically relevant. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Matsuoka, K., Bakiri, L., Bilban, M., Toegel, S., Haschemi, A., Yuan, H., Kasper, M., Windhager, R., Wagner, E. F. Tags: Open access, ARD, Animal models Source Type: research
Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort
Conclusion
With sufficient treatment duration, GLP-1RA therapies might be disease-modifying for KOA patients with comorbid T2DM, possibly mediated by weight loss. Further investigation is needed to elucidate effects of GLP-1RA on disease process, joint structure and patient-reported outcomes of osteoarthritis. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Zhu, H., Zhou, L., Wang, Q., Cai, Q., Yang, F., Jin, H., Chen, Y., Song, Y., Zhang, C. Tags: Open access, ARD, Osteoarthritis Source Type: research
Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis
Conclusion
Our findings provide compelling evidence for a profibrotic role for S100A4 in SSc and suggest that serum level may be a biomarker of major organ manifestations and disease severity. This study supports examining the therapeutic potential of targeting S100A4 in SSc. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Denton, C. P., Xu, S., Zhang, F., Maclean, R. H., Clark, K. E. N., Borchert, S., Hussain, R. I., Klingelhöfer, J., Hallen, J., Ong, V. H. Tags: ARD, Connective tissue diseases Source Type: research
Tripterygium wilfordii derivative celastrol, a YAP inhibitor, has antifibrotic effects in systemic sclerosis
Conclusions
Our data clarify niches within the skin activated in fibrosis and suggest that compounds, such as celastrol, that antagonise the YAP pathway may be potential treatments for SSc skin fibrosis. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Chitturi, P., Xu, S., Ahmed Abdi, B., Nguyen, J., Carter, D. E., Sinha, S., Arora, R., Biernaskie, J., Stratton, R. J., Leask, A. Tags: ARD, Connective tissue diseases Source Type: research
Autoantibodies identify primary Sjögrens syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B
Conclusion
We identified antigenic targets of the autoantibody response in SS that may be useful for identifying up to half of Ro seronegative SS cases. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Longobardi, S., Lopez-Davis, C., Khatri, B., Georgescu, C., Pritchett-Frazee, C., Lawrence, C., Rasmussen, A., Radfar, L., Scofield, R. H., Baer, A. N., Robinson, S. A., Darrah, E., Axtell, R. C., Pardo, G., Wren, J. D., Koelsch, K. A., Guthridge, J. M., Tags: ARD Sjo[x0308]gren ' s syndrome Source Type: research
Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
Conclusions
This is the first nation-level analysis that shows estimated and real-life direct cost-savings for TNFi biosimilars. Transparent criteria for reinvesting savings should be developed on both a local and an international levels. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Stajszczyk, M., Obarska, I., Jeka, S., Batko, B. Tags: Open access, ARD Lay summaries, ARD, Treatment Source Type: research
EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis
Conclusion
These PtC are helpful to define the clinical and imaging features of people with PsO suspicious to progress to PsA. This information will be helpful for identification of those who could benefit from a therapeutic intervention to attenuate, delay or prevent PsA development. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Zabotti, A., De Marco, G., Gossec, L., Baraliakos, X., Aletaha, D., Iagnocco, A., Gisondi, P., Balint, P. V., Bertheussen, H., Boehncke, W.-H., Damjanov, N. S., de Wit, M., Errichetti, E., Marzo-Ortega, H., Protopopov, M., Puig, L., Queiro, R., Ruscitti, Tags: ARD, Psoriatic arthritis Source Type: research
